

Nerve Agent / Organophosphate Poisoning	
The incident commander is in charge of the scene, and you are to follow his/her direction for entering and exiting the scene. Patients in the hot and warm zones MUST be decontaminated prior to entering the cold zone.	
ADULT	PEDIATRIC
BLS Procedures	
<i>Patients that are exhibiting obvious signs (SLUDGEM) of organophosphate exposure and/or nerve agents</i>	
Maintain airway and position of comfort	
Administer oxygen as indicated	
<ul style="list-style-type: none"> • Mark I or DuoDote Antidote Kit (If Available) <ul style="list-style-type: none"> ○ Mild Exposure: IM x 1 <ul style="list-style-type: none"> • May repeat in 10 minutes if symptoms persist ○ Severe Exposure: IM x 3 in rapid succession, rotating injection sites 	
ALS Standing Orders	
When Mark I or DuoDote Antidote kit is not available: <ul style="list-style-type: none"> • Atropine <ul style="list-style-type: none"> ○ Mild or Severe Exposure: ○ IV/IO – 2 mg ○ May repeat q 5 minutes for persistent symptoms If CHEMPAK deployed: <ul style="list-style-type: none"> • Diazepam <ul style="list-style-type: none"> ○ IM/IV/IO – 5 mg ○ q 10 minutes titrated to effect ○ Max 30 mg 	When Mark I or DuoDote Antidote kit is not available: <ul style="list-style-type: none"> • Atropine <ul style="list-style-type: none"> ○ Mild or Severe Exposure: ○ IV/IO – 0.05 mg/kg mg ○ May repeat q 5 minutes for persistent symptoms If CHEMPAK deployed: <ul style="list-style-type: none"> • Diazepam <ul style="list-style-type: none"> ○ IM/IV/IO - 0.1 mg/kg ○ q 10 min titrated to effect ○ Max single dose 5 mg ○ Max total dose 10 mg
Base Hospital Orders Only	
Consult with ED Physician for further treatment measures	
Additional Information: <ul style="list-style-type: none"> • DuoDote contains 2.1 mg Atropine Sulfate and 600 mg Pralidoxime Chloride. • Diazepam is available in the CHEMPACK and may be deployed in the event of a nerve agent exposure. • Mild Exposure symptoms: <ul style="list-style-type: none"> ○ Miosis, rhinorrhea, drooling, sweating, blurred vision, nausea, bradypnea or tachypnea, nervousness, fatigue, minor memory disturbances, irritability, unexplained tearing, wheezing, tachycardia, bradycardia, SOB, muscle weakness and fasciculations, GI effects. • Severe Exposure: <ul style="list-style-type: none"> ○ Abnormal behavior, severe difficulty breathing, twitching, unconsciousness, seizing, flaccid, apnea, involuntary defecation, urination. 	